New combo aims to stop breast cancer return after failed chemo
NCT ID NCT03756298
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to the chemotherapy pill capecitabine helps prevent cancer from coming back in people with triple-negative breast cancer who still had cancer after initial chemotherapy and surgery. About 284 participants will receive either the combination or capecitabine alone for 8 cycles. The study tracks how many remain cancer-free after 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab and capecitabine
What this could lead to
If successful, this combination could improve long-term survival for people with triple-negative breast cancer who still have cancer after initial chemotherapy.
What could go wrong
This is a mid-stage trial with 284 participants, so results are not yet proven. Adding atezolizumab may increase side effects like immune-related reactions without guaranteeing better outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Korea University, Guro hospital
Seoul, 08308, South Korea